HKEX Filings
-
Feb 2, 2024
Monthly Return of Equity Issuer on Movements in Securities for the Month ended January 31, 2024
-
Jan 3, 2024Monthly Return of Equity Issuer on Movements in Securities for the Month ended December 31, 2023
-
Dec 29, 2023VOLUNTARY ANNOUNCEMENT - CLOVER ANNOUNCES POSITIVE PHASE I RESULTS FOR SCB-219M FOR TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)
-
Dec 28, 2023GRANT OF EXTENSION OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14A.53 OF THE LISTING RULES UNDER THE LICENSE AGREEMENT
-
Dec 13, 2023VOLUNTARY ANNOUNCEMENT - CLOVER INITIATES PHASE I CLINICAL TRIAL FOR RSV VACCINE CANDIDATE
-
Dec 5, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended November 30, 2023
-
Nov 7, 2023VOLUNTARY ANNOUNCEMENT - CLOVER COMPLETES BLA SUBMISSION FOR SEASONAL INFLUENZA VACCINE IN BRAZIL
-
Nov 2, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended October 31, 2023
-
Nov 2, 2023(Revised)Monthly Return of Equity Issuer on Movements in Securities for the Month ended September 30, 2023
-
Oct 9, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended September 30, 2023
-
Sep 15, 2023NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS
-
Sep 15, 20232023 Interim Report
-
Sep 12, 2023VOLUNTARY ANNOUNCEMENT - CLOVER LAUNCHES QUADRIVALENT SEASONAL INFLUENZA VACCINE IN MAINLAND CHINA
-
Sep 5, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended August 31, 2023
-
Aug 23, 2023VOLUNTARY ANNOUNCEMENT INTENTION OF DIRECTOR TO INCREASE SHAREHOLDING IN THE COMPANY
-
Aug 23, 2023INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND CHANGE IN USE OF PROCEEDS
-
Aug 14, 2023POSITIVE PROFIT ALERT
-
Aug 8, 2023DATE OF BOARD MEETING
-
Aug 3, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended July 31, 2023
-
Jul 11, 2023INSIDE INFORMATION - CLOVER PROVIDES UPDATES ON BUSINESS AND R&D PIPELINE DEVELOPMENT
